HC Wainwright Issues Pessimistic Forecast for BioXcel Therapeutics (NASDAQ:BTAI) Stock Price

BioXcel Therapeutics (NASDAQ:BTAI) had its target price dropped by equities researchers at HC Wainwright from $6.00 to $5.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 323.73% from the stock’s current price. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.26) EPS and Q4 2027 earnings at ($0.26) EPS.

BTAI has been the topic of several other reports. Wall Street Zen raised BioXcel Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Rodman & Renshaw initiated coverage on BioXcel Therapeutics in a report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 price objective for the company. Zacks Research upgraded BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $11.00.

BioXcel Therapeutics Price Performance

Shares of BTAI opened at $1.18 on Thursday. The stock has a market capitalization of $31.95 million, a P/E ratio of -0.18 and a beta of 0.30. BioXcel Therapeutics has a twelve month low of $1.08 and a twelve month high of $8.08. The firm has a fifty day simple moving average of $1.54 and a two-hundred day simple moving average of $1.91.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings data on Friday, March 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.58). The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.15 million. Sell-side analysts expect that BioXcel Therapeutics will post -24.39 EPS for the current fiscal year.

Institutional Trading of BioXcel Therapeutics

Several large investors have recently bought and sold shares of the company. Oaktree Capital Management LP purchased a new position in shares of BioXcel Therapeutics during the 2nd quarter worth approximately $437,000. Oaktree Fund Advisors LLC bought a new stake in shares of BioXcel Therapeutics during the second quarter valued at approximately $78,000. Jane Street Group LLC purchased a new stake in BioXcel Therapeutics in the fourth quarter worth $204,000. State Street Corp grew its stake in BioXcel Therapeutics by 19.9% in the fourth quarter. State Street Corp now owns 63,218 shares of the company’s stock worth $101,000 after purchasing an additional 10,500 shares during the period. Finally, Man Group plc bought a new position in BioXcel Therapeutics in the fourth quarter worth $91,000. 30.68% of the stock is owned by institutional investors.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.